LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the June 19, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NYSE MKT: TXMD) securities between July 7, 2016 and April 9, 2017, inclusive (the “Class Period”). TherapeuticsMD investors have until June 19, 2017 to file a lead plaintiff motion. To obtain information or participate in the class action, please visit the TherapeuticsMD page on our website at www.glancylaw.com/case/therapeuticsmd-inc.
According to the complaint filed in this class action, TherapeuticsMD made materially false and/or misleading statements and/or failed to disclose material problems with the Company’s New Drug Application (NDA) submission for TX-004HR and that: (i) the Company’s New Drug Application (NDA) submission for TX-004HR was deficient; (ii) the Company’s NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient; and (iii) the Company’s deficient NDA would likely cause a delay of the FDA’s potential approval of the TX-004HR NDA.
If you purchased or otherwise acquired TherapeuticsMD shares during the Class Period you may move the Court no later than June 19, 2017 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.